HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

AbstractBACKGROUND:
Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non-Q-wave myocardial infarction (UA/NQMI).
METHODS AND RESULTS:
Patients (n=3910) with UA/NQMI were randomized to intravenous UFH for >/=3 days followed by subcutaneous placebo injections or uninterrupted antithrombin therapy with enoxaparin during both the acute phase (initial 30 mg intravenous bolus followed by injections of 1.0 mg/kg every 12 hours) and outpatient phase (injections every 12 hours of 40 mg for patients weighing <65 kg and 60 mg for those weighing >/=65 kg). The primary end point (death, myocardial infarction, or urgent revascularization) occurred by 8 days in 14.5% of patients in the UFH group and 12.4% of patients in the enoxaparin group (OR 0.83; 95% CI 0.69 to 1.00; P=0. 048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85; 95% CI 0.72 to 1.00; P=0.048). During the first 72 hours and also throughout the entire initial hospitalization, there was no difference in the rate of major hemorrhage in the treatment groups. During the outpatient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin (P=0.021).
CONCLUSIONS:
Enoxaparin is superior to UFH for reducing a composite of death and serious cardiac ischemic events during the acute management of UA/NQMI patients without causing a significant increase in the rate of major hemorrhage. No further relative decrease in events occurred with outpatient enoxaparin treatment, but there was an increase in the rate of major hemorrhage.
AuthorsE M Antman, C H McCabe, E P Gurfinkel, A G Turpie, P J Bernink, D Salein, A Bayes De Luna, K Fox, J M Lablanche, D Radley, J Premmereur, E Braunwald
JournalCirculation (Circulation) Vol. 100 Issue 15 Pg. 1593-601 (Oct 12 1999) ISSN: 1524-4539 [Electronic] United States
PMID10517729 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Enoxaparin
  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Isoenzymes
  • Heparin
  • Creatine Kinase
Topics
  • Acute Disease
  • Aged
  • Angina, Unstable (complications, drug therapy, surgery)
  • Anticoagulants (administration & dosage, adverse effects, therapeutic use)
  • Creatine Kinase (blood)
  • Double-Blind Method
  • Electrocardiography
  • Emergencies
  • Enoxaparin (administration & dosage, adverse effects, therapeutic use)
  • Europe (epidemiology)
  • Factor Xa Inhibitors
  • Female
  • Fibrinolytic Agents (administration & dosage, adverse effects, therapeutic use)
  • Hemorrhage (chemically induced)
  • Heparin (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Isoenzymes
  • Life Tables
  • Male
  • Middle Aged
  • Mortality
  • Myocardial Infarction (drug therapy, epidemiology, etiology, prevention & control, surgery)
  • Myocardial Revascularization (statistics & numerical data)
  • North America (epidemiology)
  • Partial Thromboplastin Time
  • Recurrence
  • Safety
  • South America (epidemiology)
  • Thrombolytic Therapy (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: